Psoriasis Treatment Center of Central New Jersey
18
8
9
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
89%
16 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Bimekizumab in Plaque Psoriasis
Role: collaborator
Upadacitinib for Prurigo Nodularis
Role: lead
Tralokinumab for Dupilumab Failures
Role: lead
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
Role: lead
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Role: lead
Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray
Role: lead
Combination of Sotyktu and Enstilar for Plaque Psoriasis
Role: lead
Topical Psoriasis Study for Patients Receiving Biologic Therapy
Role: lead
Dupixent and Narrowband UVB for Atopic Dermatitis
Role: lead
Vtama in Psoriasis Patients Being Treated With Biologics.
Role: lead
Taltz in Combination With Enstilar for Psoriasis
Role: lead
Duobrii in Combination With Biologics
Role: lead
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Role: lead
An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers
Role: lead
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Role: lead
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
Role: lead
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Role: lead
Enstilar in Combination With Biologic Agents
Role: lead
All 18 trials loaded